Hoechst merger hits setback
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.PLANS to merge Hoechst and Rhone-Poulenc, the German and French pharmaceutical giants, were put on hold at the last minute yesterday pending the approval of Hoechst's largest shareholder, the Kuwait Petroleum Corporation (KPC). Rhone-Poulenc said its board had approved plans to accelerate a merger but later cancelled a scheduled press conference to explain the deal. The merger, which would create the world's biggest drug maker, would require both companies to sell most of their chemicals businesses during a downturn in the chemicals cycle.
In February KPC, which owns 24.5 per cent of Hoechst, said the merger did not serve its interests on the terms then suggested.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments